Enigma Teams with GlaxoSmithKline on Flu MDx | GenomeWeb

NEW YORK (GenomeWeb News) – UK-based molecular diagnostics startup Enigma Diagnostics has inked an agreement with GlaxoSmithKline to develop and market point-of-care influenza tests that will run on Enigma's PCR-based platform, Enigma ML.

Under terms of the worldwide development and supply deal, GSK will make a small, undisclosed equity investment in Enigma. It also will provide Enigma with an upfront payment, research and development funding, milestone payments, and profit sharing on sales of products developed under the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.